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ABSTRACT  
 
Objective: To examine the diagnostic accuracy of a previously developed model for 
prediction of preeclampsia (PE) by a combination of maternal factors and biomarkers at 11-
13 weeks’ gestation. 
 
Methods: This was a prospective first-trimester multicenter study of screening for PE in 
8,775 singleton pregnancies. A previously published algorithm was used for the calculation 
of patient-specific risk of PE in each patient. The detection rates (DR) and false positive 
rates (FPR) for delivery with PE at <32, <37 and >37 weeks were estimated and compared 
to those in the dataset used for development of the algorithm. 
 
Results: In the study population there were 239 (2.7%) cases that developed PE, including 
17 (0.2%), 59 (0.7%) and 180 (2.0%) at <32, <37 and >37 weeks, respectively. In combined 
screening by maternal factors, mean arterial pressure, uterine artery pulsatility index and 
serum placental growth factor the DR was 100% (95% CI 80-100) for PE at <32 weeks, 75% 
(95% CI 62-85) for PE at <37 weeks and 43% (95% CI 35-50) for PE at >37 weeks, at 10%  
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FPR. These DRs were similar to the estimated rates in the dataset used for development of 
the model: 89% (95% CI 79-96) for PE at <32 weeks, 75% (95% CI 70-80) for PE at <37 
weeks and 47% (95% CI 44-51) for PE at >37 weeks. 
 
Conclusion: Combination of maternal factors and biomarkers provides effective first-
trimester screening for preterm-PE. 
 
 
 
 
 
 
Key words: First-trimester screening, Preeclampsia, Pyramid of pregnancy care, Survival 
model, Bayes theorem, Uterine artery Doppler, Mean arterial pressure, Pregnancy 
associated plasma protein-A, Placental growth factor. 
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INTRODUCTION 
 
Scientific and clinical background 
 
Effective screening for preterm preeclampsia (PE) can be provided at 11-13 weeks’ 
gestation by a combination of maternal characteristics and medical history (maternal factors) 
with multiple of the median (MoM) values of mean arterial pressure (MAP), uterine artery 
pulsatility index (UTPI) and serum placental growth factor (PLGF) and pregnancy associated 
plasma protein-A (PAPP-A). In a previous study we used data from prospective screening in 
35,948 singleton pregnancies at 11-13 weeks to develop an algorithm for the calculation of 
patient-specific risk of PE.1 Bayes theorem was used to combine the a priori risk from 
maternal factors2 with various combinations of MAP, UTPI, PAPP-A and PLGF.1 In 
pregnancies with PE the deviation from normal for each biomarker was inversely related to 
the gestational age at delivery and consequently the performance of screening  was greater 
for early than late PE. The performance of each biomarker in combination with maternal 
factors was superior to that of screening by maternal factors alone. Similarly, the 
performance by a combination of two or more biomarkers was superior to that of screening 
by individual biomarkers. The only exception was serum PAPP-A, which did not provide 
significant improvement to any combination of biomarkers which included serum PLGF. In 
combined screening by maternal factors, MAP, UTPI and PLGF the detection rate (DR) of 
delivery with PE at <32, <37 and >37 weeks was 89%, 75% and 47%, respectively, at false 
positive rate (FPR) of 10%. A limitation of the study is that the performance of screening by a 
model derived and tested using the same dataset may be overestimated.  
 
Study objectives and hypothesis 
 
The objective of this study is to report the accuracy of the previously reported first-trimester 
model of screening for PE 1 in a prospective, non-intervention, multicenter study in 8,775 
singleton pregnancies. The hypothesis is that the performance of screening would be similar 
to that estimated from the original model 1. 
 
The Standards for Reporting Diagnostic accuracy studies (STARD) 3 were adhered to. 
 
 
METHODS 
 
Study design and participants 
 
This was a prospective, non-intervention, multicenter study in singleton pregnancies at 11+0 -
13+6 weeks’ gestation in women booking for routine pregnancy care at King’s College 
Hospital, London, UK, Medway Maritime Hospital, Gillingham, UK, Homerton University 
Hospital, London, UK, North Middlesex University Hospital, London, UK, Southend 
University Hospital, Essex, UK, Lewisham University Hospital, London, UK, Hospital Clínico 
Universitario Virgen de la Arrixaca, Murcia, Spain, Hospital Universitario San Cecilio, 
Granada, Spain, Hospiten Sur, Tenerife, Spain, Centre Hospitalier Universitaire Brugmann, 
Brussels Belgium, Attikon University Hospital, Athens, Greece and Ospedale Maggiore 
Policlinico, Milan, Italy. The women were screened between February and September 2015 
and gave written informed consent to participate in the study, which was approved by the 
NHS Research Ethics Committee in the UK and the Ethics Committee of each participating 
hospital in other countries. 
 
The eligibility criteria were maternal age >18 years, no serious mental illness or learning 
difficulties, singleton pregnancy with live fetus demonstrated on the 11-13 weeks scan and 
subsequent delivery of a phenotypically normal live birth or stillbirth at >24 weeks’ gestation. 
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We excluded multiple pregnancies, those with aneuploidies or major fetal abnormalities and 
those ending in termination or miscarriage. 
 
Test methods 
 
The index test, or test whose accuracy has been evaluated, is the previously reported 
algorithm for first-trimester assessment of risk for PE by maternal factors and various 
combinations of MAP, UTPI, PAPP-AS and PLGF.1 Maternal factors were recorded,2 MAP 
was measured by validated automated devices and standardized protocol,4 transabdominal 
color Doppler ultrasound was used to measure the left and right UTPI and the average value 
was recorded,5 serum PAPP-A and PLGF concentrations were measured by an automated 
device (PAPP-A and PlGF 1-2-3TM kits, DELFIA® Xpress random access platform; 
PerkinElmer Inc. Wallac Oy, P.O.Box 10, 20101 Turku, Finland). All operators undertaking 
the Doppler studies had received the appropriate Certificate of Competence from the Fetal 
Medicine Foundation. Measured values of MAP, UTPI, PAPP-A and PLGF were expressed 
as a MoM adjusting for those characteristics found to provide a substantive contribution to 
the log10 transformed value including the maternal factors in the prior model.6-9 
 
The index test was carried out prospectively in consecutive singleton pregnancies at 11+0 -
13+6 weeks’ gestation; gestational age was determined from the measurement of fetal 
crown-rump length.10 The results from screening were not made available to the patients or 
their physicians. 
 
The target condition was PE, as defined by the International Society for the Study of 
Hypertension in Pregnancy.11 The systolic blood pressure should be >140 mm Hg and/or the 
diastolic blood pressure should be >90 mmHg on at least two occasions four hours apart 
developing after 20 weeks of gestation in previously normotensive women. Hypertention 
should be accompanied by proteinuria of >300 mg in 24 hours or two readings of at least ++ 
on dipstick analysis of midstream or catheter urine specimens if no 24-hour collection is 
available. In PE superimposed on chronic hypertension significant proteinuria (as defined 
above) should develop after 20 weeks of gestation in women with known chronic 
hypertension (history of hypertension before conception or the presence of hypertension at 
the booking visit before 20 weeks’ gestation in the absence of trophoblastic disease).  
Data on pregnancy outcome were collected from the hospital maternity records of the 
women. The obstetric records of all women with pre-existing or pregnancy associated 
hypertension were examined to determine if the condition was PE  
 
Analysis 
 
The previously described algorithm was used for the calculation of patient-specific risk of 
delivery with PE at <32, <37 and >37 weeks’ gestation.1 The pre-specified analyses for 
performance of screening for maternal factors and any combinations of maternal factors with 
MAP, UTPI, PAPP-A and PLGF were estimation of areas under the receiver operating 
characteristic curve (AUC) and DR, with 95% CI, at FPR of 5% and 10%. 
 
The statistical software package R was used for data analyses.12 
 
 
RESULTS 
 
Participants  
 
During the study period, 9,041 pregnancies meeting the inclusion criteria underwent 
screening for PE. We subsequently excluded 266 (2.9%) cases because they had a major 
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fetal defect (n=33), the pregnancy resulted in termination (n=39) or miscarriage (n=88) or 
there was no follow up (n=106). 
 
In the study population there were 239 (2.7%) cases that developed PE, including 17 (0.2%), 
59 (0.7%) and 180 (2.0%) at <32, <37 and >37 weeks, respectively. Baseline demographic 
and clinical characteristics of participants are shown in Table 1. In total, 12 maternity 
hospitals in five different countries were involved in patient recruitment, 127 doctors 
participated in the measurement of UTPI and 152 doctors or nurses were involved in the 
measurement of MAP. 
 
Test results 
 
The AUC and DR at FPR of 5% and 10% of delivery with PE at <32, <37 and >37 weeks’ 
gestation in screening by maternal factors and biomarkers using the previously reported 
algorithm1 are given in Table 2 and compared to previously reported values in Figures 1-3. 
The DRs in the validation dataset were very similar to the estimated rates in the dataset 
used for development of the model. 
 
The performance of screening for PE at <37 weeks was superior to that of PE at >37 weeks. 
The best performance of screening was achieved by a combination of maternal factors, 
MAP, UTPI and PLGF and this was not improved by addition of PAPP-A.  
 
 
DISCUSSION 
 
Main findings 
 
This prospective multicenter validation study demonstrates the feasibility of incorporating 
first-trimester screening for PE into routine clinical practice. The findings demonstrate that 
the performance of screening for PE at 11-13 weeks by a combination of maternal factors 
and biomarkers is similar to that estimated from the original model.1 The DR of screening by 
maternal factors, MAP, UTPI and PLGF, at 10% FPR, was 100% (95% CI 80-100) for PE at 
<32 weeks, 75% (95% CI 62-85) for PE at <37 weeks and 43% (95% CI 35-50) for PE at 
>37 weeks; the estimated rates in the dataset used for development of the model were 89% 
(95% CI 79-96), 75% (95% CI 70-80) and 47% (95% CI 44-51), respectively.1 
 
Study limitations  
 
The main limitation of the study relates to the low incidence of delivery with PE with the 
inevitable wide confidence intervals obtained for performance of screening. Nevertheless, 
the values obtained in the validation study are very similar to those in the dataset of 35,948 
pregnancies used for development of the algorithm. 
 
Implications for practice 
 
Screening and diagnosis of PE is traditionally based on the demonstration of elevated blood 
pressure and proteinuria during a routine clinical visit in the late second- or third-trimester of 
pregnancy. In a proposed new pyramid of pregnancy care,13 assessment of risk at 11-13 
weeks’ gestation aims to identify pregnancies at high-risk of developing PE and through 
pharmacological intervention, with such medications as low-dose aspirin, to reduce the 
prevalence of these complications.14,15  
 
The findings of the validation study confirm that screening at 11-13 weeks identifies a high 
proportion of cases that will develop PE at <37 weeks, but the performance of screening at 
this stage for PE at >37 weeks is poor.1 This is particularly important because the 
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prophylactic use of low-dose aspirin is effective in the prevention of preterm-PE rather than 
term-PE.16 We have previously reported that effective prediction of PE at >37 weeks requires 
screening at 35-36 weeks.17 
 
 
Sources of Funding: The study was supported by grants from the Fetal Medicine Foundation 
(Charity No: 1037116) and by the European Union 7th Framework Programme - FP7-
HEALTH-2013-INNOVATION-2 (ASPRE Project # 601852).  
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Figure legends 
 
 
Figure 1. Detection rate with 95% confidence interval at 10% false positive rate of screening 
for delivery with preeclampsia at <32 weeks’ gestation by maternal factors and combinations 
of biomarkers. The black circles and lines represent the values obtained in the dataset used 
for development of the algorithm1 and the red circles and lines represent the values obtained 
in the validation dataset. MAP = Mean arterial pressure; UTPI = Uterine artery pulsatility 
index; PAPP-A = Pregnancy associated plasma protein-A; PLGF = Placental growth factor. 
 
Figure 2. Detection rate with 95% confidence interval at 10% false positive rate of screening 
for delivery with preeclampsia at <37 weeks’ gestation by maternal factors and combinations 
of biomarkers. The black circles and lines represent the values obtained in the dataset used 
for development of the algorithm1 and the red circles and lines represent the values obtained 
in the validation dataset. MAP = Mean arterial pressure; UTPI = Uterine artery pulsatility 
index; PAPP-A = Pregnancy associated plasma protein-A; PLGF = Placental growth factor. 
 
Figure 3. Detection rate with 95% confidence interval at 10% false positive rate of screening 
for delivery with preeclampsia at >37 weeks’ gestation by maternal factors and combinations 
of biomarkers. The black circles and lines represent the values obtained in the dataset used 
for development of the algorithm1 and the red circles and lines represent the values obtained 
in the validation dataset. MAP = Mean arterial pressure; UTPI = Uterine artery pulsatility 
index; PAPP-A = Pregnancy associated plasma protein-A; PLGF = Placental growth factor. 
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Table 1: Characteristics of study population.  
 
 
IQR = interquartile range; SLE = systemic lupus erythematosus; APS = antiphospholipid syndrome; 
Comparisons between outcome groups were by chi-square or Fisher exact test for categorical 
variables and Mann Whitney-U test for continuous variables 
 Maternal characteristics 
Delivery with preeclampsia 
None (n=8,624) <32 (n=17) <37 (n=59) >37 (n=180) 
Maternal age in years, median (IQR) 31.5 (27.3, 35.0) 29.8 (26.7, 34.6) 30.6 (25.95, 34.7) 31.2 (27.8, 34.8) 
Maternal weight in Kg, median (IQR) 66.2 (58.8, 76.9) 72.6 (65.6, 86.0) 69.8 (63.0, 87.8) 75.0 (64.925, 84.0) 
Maternal height in cm, median (IQR) 165 (160, 169) 164 (161, 166) 164 (160, 169) 164 (159, 168) 
Body mass index, median (IQR) 24.5 (21.9, 28.3) 27.3 (23.9, 31.8) 27.1 (23.6, 31.82) 27.8 (23.9, 31.5) 
Gestational age in weeks, median (IQR) 12.7 (12.3, 13.1) 12.6 (12.3, 12.7) 12.7 (12.4, 13.0) 12.7 (12.3, 13.2) 
Racial origin, n (%)   
  Caucasian 6,768 (78.5) 8 (47.1) 38 (64.4) 129 (71.7) 
  Afro-Caribbean 1,068 (12.4) 8 (47.1) 14 (23.7) 36 (20.0) 
  East Asian 154 (1.8) 0 (0.0) 0 (0.0) 1 (0.6) 
  South Asian 451 (5.2) 0 (0.0) 3 (5.1) 12 (6.7) 
  Mixed 183 (2.1) 1 (5.9) 4 (6.8) 2 (1.1) 
Medical history, n (%)   
  Chronic hypertension 79 (0.9) 3 (17.7) 9 (15.3) 16 (8.9) 
  Diabetes mellitus 64 (0.7) 2 (11.8) 3 (5.1) 2 (1.1) 
  SLE or  APS 19 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 
Cigarette smoking, n (%)   7,901 (91.6) 16 (94.1) 55 (93.2) 169 (93.9) 
Family history of preeclampsia, n (%)   441 (5.1) 1 (5.9) 7 (11.9) 17 (9.4) 
Conception, n (%)   
  Spontaneous 8,340 (96.7) 17 (100) 57 (96.6) 173 (96.1) 
  In vitro fertilization 219 (2.5) 0 (0.0) 2 (3.4) 7 (3.9) 
  Ovulation drugs 64 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 
Parity, n (%)   
  Nulliparous 4,008 (46.5) 11 (64.7) 36 (61.0) 119 (66.1) 
  Parous: no previous preeclampsia 4,445 (51.5) 4 (23.5) 17 (28.8) 46 (25.6) 
  Parous: previous preeclampsia 171 (2.0) 2 (11.8) 6 (10.2) 15 (8.3) 
Pregnancy interval in years, median (IQR) 2.7 (1.6, 4.6) 5.4 (4.3, 7.2) 4.1 (2.4, 6.8) 3.4 (2.0, 5.4) 
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 Table 2. Performance of screening for delivery with preeclampsia at <32, <37 and >37 weeks’ gestation in the validation dataset using a 
previously developed algorithm based on maternal factors and combinations of biomarkers.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUC = area under the receiver operating characteristic curve; FPR = false positive rate; MAP = Mean arterial pressure; UTPI = Uterine artery pulsatility 
index; PAPP-A = Pregnancy associated plasma protein-A; PLGF = Placental growth factor 
 
Method of screening 
Preeclampsia at <32w (n=17) Preeclampsia at <37w (n=59) Preeclampsia at >37w (n=180)
AUC 
Detection rate at: 
AUC 
Detection rate at: 
AUC 
Detection rate at: 
FPR 5% FPR 10% FPR 5% FPR 10% FPR 5% FPR 10% 
Maternal factors 0.8045 41 (18, 67) 53 (28, 77) 0.7583 29 (18, 42) 41 (28, 54) 0.7449 18 (13,25) 37 (30, 45)
Maternal factors plus: 
MAP 0.9071 59 (33, 82) 71 (44, 90) 0.8243 36 (24, 49) 47 (34, 61) 0.7789 26 (20, 33) 37 (30, 45)
UTPI 0.9309 71 (44, 90) 82 (57, 96) 0.8537 47 (34, 61) 61 (47, 73) 0.7539 22 (16, 29) 39 (32, 47)
PAPP-A 0.8546 47 (23, 72) 59 (33, 82) 0.7825 37 (25, 51) 47 (34, 61) 0.7504 21 (15, 28) 37 (30, 44)
PLGF 0.9506 65 (38, 86) 88 (64, 99) 0.8722 49 (36, 63) 63 (49, 75) 0.7578 20 (14, 27) 39 (32, 46)
MAP, UTPI 0.9667 82 (57, 96) 94 (71, 100) 0.8958 53 (39, 66) 71 (58, 82) 0.7875 27 (20, 34) 41 (34, 49)
MAP, PAPP-A 0.9133 65 (38, 86) 76 (50, 93) 0.8342 41 (28, 54) 49 (36, 63) 0.7827 28 (21, 35) 40 (33, 48)
MAP, PLGF 0.9674 76 (50, 93) 88 (64, 99) 0.8985 53 (39, 66) 69 (56, 81) 0.7870 29 (22, 36) 43 (36, 51)
UTPI, PAPP-A 0.9339 71 (44, 90) 82 (57, 96) 0.8583 49 (36, 63) 66 (53, 78) 0.7571 24 (18, 31) 40 (33, 48)
UTPI, PLGF 0.9772 82 (57, 96) 100 (80, 100) 0.9000 61 (47, 73) 75 (62, 85) 0.7619 22 (16, 29) 39 (32, 47)
PLGF, PAPP-A 0.9510 65 (38, 86) 88 (64, 99) 0.8741 51 (37, 64) 66 (53, 78) 0.7589 20 (14, 27) 39 (32, 47)
MAP, UTPI, PAPP-A 0.9644 88 (64, 99) 94 (71, 100) 0.8956 61 (47, 73) 69 (56, 81) 0.7892 29 (22, 36) 42 (35, 50)
MAP, PAPP-A, PLGF 0.9672 76 (50, 93) 88 (64, 99) 0.8998 54 (41, 67) 69 (56, 81) 0.7882 29 (22, 36) 43 (36, 51)
MAP, UTPI, PLGF 0.9870 94 (71, 100) 100 (80, 100) 0.9242 66 (53, 78) 75 (62, 85) 0.7916 32 (25, 39) 43 (35, 50)
UTPI, PAPP-A, PLGF 0.9769 82 (57, 96) 100 (80, 100) 0.9004 61 (47, 73) 75 (62, 85) 0.7626 23 (17, 30) 38 (31, 46)
MAP, UTPI, PAPP-A, PLGF 0.9865 94 (71, 100) 100 (80, 100) 0.9241 66 (53, 78) 80 (67, 89) 0.7923 31 (24, 38) 43 (35, 50)
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